In this paper the authors investigated a synergistic antimycotic effect between four antifungal drugs Amphotericin B, Fluconazole, Tioconazole, and Flucytosine individually combined with Anidulafungin compound. This latter is considered a drug of choice in the treatment of fungal infections; it has good activity both in vitro and in vivo against yeasts and moulds, as Candida and Aspergillus. The goal of this study was to evaluate the in vitro interaction of Anidulafungin in the synergic combinations with previous reported drugs against 12 Candida strains according to CLSI M27-A3 protocol. A synergistic interaction was observed against the most antifungal strains; in particular an increasing of the antimycotic efficacy was obtained from the association between Anidulafungin and Amphotericin B or Fluconazole (Mixture 4:6). In contrast the association Tioconazole/Anidulafungin was less effective on fungal species growth. The antimycotics MIC reduction values were more evident against some strains as C. glabrata, C. krusei, C. tropicalis and C. parapsilosis.
INTRODUCTION
The emergence of opportunistic fungal pathogens, the increased variety of mycoses, the recovery of clinical isolates resistant to conventional antifungal agents and the adverse side effects of Amphotericin B and azole have promoted the development of new antifungal agent as well as of lipid formulations of Amphotericin B and Nystatin. Invasive fungal infection due to yeast are becoming more prevalent in immuno compromised patients and result in significant morbidity and mortality rates. Candidiasis is one of the most frequent opportunistic fungal infections. The most common species associated with candidemia remains Candida albicans (50% to 60% of cases) but non-C. albicans species, especially C. glabrata (20% of case) followed by C. parapsilosis, C. tropicalis, and C. krusei, have merged as significant pathogens. [1] [2] [3] [4] [5] . In particular C. parapsilosis is the second most frequent yeast species isolated from normally sterile body sites in North America, Europe, and Latin America [6, 7] . Moreover studies conducted in the United States showed that C. parapsilosis is the most common non Calbicans in pediatric patients [8, 9] . C. glabrata has recently emerged as a significant systemic pathogen and oral and vaginal infections are being reported. Many isolates of C. glabrata have shown innate resistance to azole and as a consequence the pharmacological treatment often fails. Com-bined therapy could be a therapeutic alternative, but it has been poorly explored [10] . The availability of new antifungal agents with novel mechanisms of action has stimulated renewed interest in combination antifungal therapies. The efficacy of antifungal drugs in combination with respect to the growth of fungal pathogens can impact efficacy when these agents are used together. It is not obvious that the use of two or more effective drugs with different mechanism of action will produce an improved outcome compared to the results observed with a single agents. Different in vitro studies have attempted to characterize interactions among antifungal agents developed for the treatment of Candida spp. infections and various results, have been obtained. Among different synergistic investigations against Candida spp. focused on interaction between polyenes and azole drugs. In addition, other drugs such as Flucytosine-azole, azole -echinocandin and polyenes with echinocandin against Candida spp. have been studied. Echinocandin combination studies have been somewhat unimpressive; while these studies have not demonstrated antagonism, synergy has also been observed infrequently [11] . Probably, the echinocandin fungicidal activity against most Candida spp. is observed if it is administered alone. Fluconazole (FLU) may inhibit Caspofungin activity against Candida albicans strains biofilm, whereas caspofungin and Amphotericin B (AMB) appeared to have indifferent effects [12] . Only few data have been reported on combination echinocandin and current antifungal agents against non-Candida species. It is worthy to note that is a class of semisynthetic lipopeptide antifungal compounds that inhibit synthesis of 1,3--D glucan a key component of the cell walls of major part of pathogenetic fungi. Among this class of compounds, Anidulafungin is a semisynthetic echinocandin under development for the treatment of fungal infections including invasive candidiasis. It is important to underline that this compound showed antifungal activity against a lot of Candida spp. resistant to Amphotericin B. On the base of these considerations, here in we describe a reliable method to study the in vitro synergistic effects of drugs such as, Fuconazole, Tioconazole (TIO), a polyene, Amphotericin B and 5-Flucytosine (5FC), individually combined with concentrations of Anidulafungin (ANF) ranging from 25% to 40%, against a large panel Candida strains both ATCC and clinical isolated. These last one were isolated from blood samples specimens affected by invasive candidiasis. Four clinical strains were isolated from patients with invasive candidiasis and all isolates were obtained from blood samples or specimens from normally sterile sites. The isolates were identified to species level by conventional methods [13] . The synergistic results of the examined antifungal drugs in combination with Anidulafungin were carried out by using the CLSI M27-A3 protocol that deals with microdilution method. The recorded results could be useful in the choice of synergistic antifungal therapy, especially in view of the high cost of new drugs and the potential for antagonistic interactions.
EXPERIMENTAL SECTION

Material and Method
The antifungal agents Fluconazole, Tioconazole, 5-Flucytosine and Amphotericin B were purchased from Sigma (Milano, Italy) and Anidulafungin was supplied by the Pfizer (Rome, Italy)
Fungal Strains and Antimicrobial Testing
The following control fungal (American Type Culture Collection (ATCC, Rockville, MD, USA)) and isolates strains were used to test the antifungal activities of the mixture: The isolates were subcultured twice on Sabouraud dextrose agar before they were tested. Yeast cells were washed in sterile saline four times. Each fungal suspension was originated from a frozen stock at -70°C containing each strain. The strain was inoculated in 5 ml of Sabouraud dextrose broth and incubated under stirring for 48 h at 35°C.
A small quantity of inocula was dissolved in RPMI 2% glucose and then spectrophothometrically adjusted to 0.5 x 10 -3 to 2.5x 10 -3 CFU/ mL (Mac Farland turbidity standard). The starting inocula were confirmed by plating serial dilutions and determining the colony counts. A total of 0.1 ml of each yeast suspension was dispensed into serially diluted wells containing the drugs, reaching the final drug concentration. The MIC of four antifungal agents were determined by the broth microdilution method, according to the CLSI (Clinical and Laboratory Standard Institute, 2008) protocol M27-A3 guidelines. After the addition of 0.1 mL of inoculum, the plates were incubated at 36° C for 24 hours. MIC was defined as the lowest concentration of the mixtures that did not results in any visible growth of the fungal strains compared to their growth in the control well. The MIC values are given in g/ml for all the antifungal agents. MIC determination were realized in four independent assays. MIC data of the antifungal agents and Anidulafungin were converted into Fractional Inhibitory Concentration (FIC) determined for each drug by dividing the MIC of each drug when used in combination by the MIC of each drug when used alone [14] .
Microdilution Checkerboard Method
In the combination assays the checkerboard procedure described by White et al. [15] was followed to evaluate the synergistic action of the four antifungal substances and Anidulafungin.
In our experimental procedures we applied some modifications to CLSI protocol. Pure powders of ANF (Pfizer), TIO (Sigma), 5FC (Sigma), FLU (Sigma) and AMB were dissolved to obtain stock solution concentration of 2 g/ml: serial dilution were made to 0.4 g/ml. A Checkerboard testing was carried out in RPMI 2% glucose in microdilution plates by using elements from CLSI M27-A3. Drug dilutions in two fold increments were prepared at fourfold levels above the concentration for each drug tested. Each wells contained combination drugs made at 50 l each, in this way forming a 2x concentration of each drug. In the first step of our experiment the serial dilutions ranged from 40% to 5% for Anidulafungin and from 25% to 3.12% for the antimycotics (TIO, 5FC, FLU and AMB) in the second step we used an higher percentage of the four antimycotics (40%, 20%, 10%, 5%) and lower percentage of Anidulafungin (25%, 12.5%, 6.25%, 3.12%). Microdilution checkerboard method was used to mix all Anidulafungin dilutions with the appropriate concentrations of the antifungal drugs. In this way it has been possible to obtain a series of concentrations combination of the Anidulafungin/antimycotic agent. In our experimental protocol the combinations of the substances were analysed by calculating the FIC index (FICI) as follows: FIC of antimycotic agent plus FIC of Anidulafungin. Generally, FICI value was interpreted as : i) a synergistic effect when it is 0.5; ii) an additive or indifferent effect when it is > 0.5 and <1; iii) an antagonistic effect when it is > 1 [14] . Generally, the combination of the two components can be shown graphically in a Cartesian diagram by applying the isobole method. The non-interaction of the two components results in a straight line, whereas the occurrence of an interaction is shown by a concave isobole [16] [17] [18] [19] [20] .
RESULTS
In this study four antimycotics drugs, Amphotericin B, Fluconazole, Tioconazole, 5-Flucytosine were used in association with Anidulafungin, a new generation echinocandin compound. The effects of their associations of these antimycotics were evaluated on a large panel of yeasts. The obtained results are reported in Table 1 , Table 2 and in Table 3 . In detail, Table 1 shows first series of experiments with Anidulafungin concentrations ranged from 40% to 5% of the MICs and the four antimycotics concentrations ranged from 25% to 3,12% of the MICs. MICo (MIC of an individual sample) and MICc (MIC of an individual sample at the most effective combination) and FIC for AMB respectively ranged from 0.5 to 1 g/mL, 0.01 to 0.4 g/mL, and 0.05 to 0.4 g/mL. The MICo, MICc, and FIC of FLU ranged from 0.5 to 16 g/mL, 0.05 to 1 g/mL, and 0.03 to 0.4 g/mL, while the MICo, MICc, and FIC of TIO ranged from 0.03 to 2 g/mL, 0.001 to 0.06 g/mL, and 0.03 to 0.4 g/mL. Furthermore, the MICo, MICc, and FIC of % 5FC ranged from 0.5 to 8 g/mL, 0.015 to 0.4 g/mL, and 0.03 to 0.4 g/mL. Lastly, the MICo, MICc, and FIC of the Anidulafungin ranged from 0.001 to 1 g/mL, 0.001 to 0.4 g /mL, and 0.03 to 0.4 g /mL.
In Table 2 are reported the second series of experiments with Anidulafungin concentrations ranged from 25 % to 3.12 %, and the four antimycotics drugs concentrations ranged from 40% to 5% of the MICs.
MICo and MICc and FIC for AMB respectively ranged from 0.5 to 1 g/mL, 0.015 to 0.4 g/mL and 0.03 to 0.4 g/mL. The MICo, MICc, and FIC of FLU ranged from 1 to 16 g/mL, 0.02 to 6.4 g/mL, and 0.05 to 0.4 g/mL, while the MICo, MICc, and FIC of TIO ranged from 0.03 to 2 g/mL, 0.001 to 0.1 g/mL, and 0.03 to 0.4 g/mL. Furthermore, the MICo, MICc, and FIC of 5FC ranged from 0.5 to 8 g/mL, 0.025 to 2 g/mL, and 0.05 to 0.4 g/mL. Lastly, the MICo, MICc, and FIC of the Anidulafungin ranged from 0.01 to 1 g/mL, 0.0002 to 0.25 g /mL, and 0.03 to 0.4 g /mL. In particular on Table 1 is reported a reduction of the antimycotics efficacy doses against both the Candida and no-Candida species, if the drugs are used in association with Anidulafungin (40%). The association between Anidulafungin and AMB gives rise to a decrease of MICo of AMB in all yeast strains; the combination was 2.5 to 100-fold more potent than each agent administered as alone. Particularly interesting is the MIC value reduction observed for C. krusei ATCC 14423 ranged from 1 to 0.01 μg /mL (100 times). The association FLU /Anidulafungin and TIO/Anidulafungin show the same profile: the first association produced a MIC reduction ranged from 4 to 33 times. It is interesting to underline that C. krusei ATCC 14423 MIC ranged from 16 to 0.48 μg /mL. The association TIO/ Anidulafungin gives rise a MIC reduction ranged from 2.5 to 100 times observed in for C. krusei, glabrata and parapsilosis. Finally 5FC MIC reduction ranged from 2.5 to 33 times. A significant effect was obtained on C. krusei 31A129 clinical isolate.
Generally, all examined mixtures show good synergic effects on the most fungal strains. The best result is obtained in the combination experiments of FLU/Anidulafungin and 5FC/Anidulafungin against 10 fungal strains showed a FICI value <0.5. The table 2 shows the MIC values for the same association, antimycotic drugs /Anidulafungin, are the same reported in Table 1 ; while the percentage of Anidulafungin is in the dilution range of 25%-3.12%.
The data obtained show a decrease of activity in terms of FICI. Among the eleven studied strains reported in Table 1 , only six strains show a FICI <0.1. It is worth noting that in case of Candida Albicans species the decrease of Anidulafungin percentage in association with AMB and FLU or TIO produces a more significative synergic effect according to previous evidence reported in literature [21] .
The table 3 compare the FICI values reported both on Table 1 and 2. The dark areas of table represent the decrease of FICIs (better synergistic effect) while the clear areas indicate the non increase of FICIs moving from a lower to a higher percentage of anidulafungin for considered mixtures.
The association AMB/Anidulafungin gives rise to a good synergistic effect for 7 fungal strains, with a decrease of the FICI, moving from a lower (25%) to a higher (40%) percentage of Anidulafungin. The same effect is showed by FLU (for six fungal strains), by TIO (for five fungal strains) and by 5FC (for 4 fungal strains). Figures 1, 2, 3 and 4 describe the synergistic interaction between the Anidulafungin and the various antimycotic drugs respectively towards the Candida guilliermondii, ATCC 6260 and two clinical isolates Candida glabrata 18A19, and Candida krusei 31A29. The combination of the two components is shown by most common graphic representation called isobologram (iso-effect curve). It is worthy to note that an isobologram is constructed by outlining on the x and the y axes, which are the inhibitory doses of the two agents, for a given effect. If the effect is additive, the totalled doses are proportional to the effect, which is verified by a shift towards the straight line on the graph, which connects two doses with equal effects, a linear isobole, when the agents are not synergic. When the curve of the isobole moves towards the origin (concave line) this indicates that the agents in the mixture are synergic, and when the opposite occurs (convex line) they present antagonism. In the other words, the same biological effects of the agents in isolation is obtained at lower (or higher) doses of mixture [22] . In the Figs. (1, 2, 3 and 4) the considered strains showed a significative decrease in presence of mixture Anidulafungina/antimycotic ranged 40%-25%. In the graphs it is possible to note how the isobole points for the reported non-Candida albicans strains are closer to the origin of the axes when the percentage of Anidulafungin in the mixture increases to 40%.
DISCUSSION
Opportunistic yeast infections such as candidiasis, occur particularly in immuno-compromised patients. The treat- ments of these infective affections are a problem for the actual therapies. Nowadays only few antifungal agents are available, and their efficacy is not always optimal; several drugs can cause toxicity, and resistance to the new agents. The approach to this problem can be the combination of different antifungal therapies. In particular and despite the limited clinical data, the high mortality of mould infections and the relatively limited efficacy of current agents have produced significative interest in polyene-, extended-spectrum azole-, and echinocandin -based combinations for these difficult to treat infections. In the light of these evidence in this paper the in vitro results of the associations between Anidulafungin and the most antifungal agents commercially available such as polyene AMB, azole FLU, TIO, and 5FC are reported. The latter is a drug with limited spectrum of action that includes Candida spp.; the drug preferably is given in combination with other antifungal agents because the monotherapy with 5FC produces resistance. The use of 5FC as a single agent is limited to the treatment of cases of chromoblastomycosis, uncomplicated lower urinary tract can- didiasis, and vaginal candidiasis. In the most cases, 5FC is used concomitantly with other agents, mainly AMB [23] for the treatment of systemic mycosis, such as Cryptococcosis, Candidiasis, and Aspergillosis [24] . However, there is no evidence that this combination is more effective than AMB monotherapy in the treatment of both invasive Candidal infections and invasive Aspergillosis [24] . AMB is considered to be the principal drug for treating fungal infections and is often combined with other antifungal drugs such as azole [25, 26] . Recently there has been an increase in data reporting the resistance of C. albicans to the azole. For this reason it has now become very important to reduce the AMB dose by combining it with a new product that has antifungal properties [27] . Moreover the combination antifungal therapy, in some cases, could reduce antifungal killing and clinical efficacy: for example it has been reported the potential antagonism observed between azole and polyenes in the treatment of aspergillosis [28] . FLU and TIO show efficacy and safety in topical preparations and have an unusual fungicidal activity because they destroyed yeast cells in the stationary phase. Their action with a characteristic of fungicidal activity was directed against the membrane [29] . A lot of associations between polyene -azole and other agents showing divergent views have been reported. The guidelines of Infectious Diseases Society of America (2004) advise the Caspofungin, an echinocandin compound, as elective drug for treatment of invasive candidiasis both for its broad spectrun of action (Candida and non-Candida spp.) and for the best index safety in terms of adverse effects. Moreover the large use of FLU in the treatment of candidiasis gave rise to a resistance above all for the non-Candida strains such C. krusei, and C. glabrata. There is a broad experience that demonstrates, in several tests and experiments, the efficacy of Echinocandins, and Anidulafungin in particular [30] . In the light of these evidences and as a part of our ongoing research program [31] [32] [33] in this study we report the antimicrobial activity of Anidulafungin evaluated in association with four antifungal agents on a large panel of Candida species from collection and isolates too. The combination of an higher quantity of Anidulafungin (from 25% to 40%) with the four antimycotics administered, against fungal species under consideration, is likely to reduce antimycotics minimum effect dose. In fact as reported in Table 1 and 2 and confirmed in Table 3 , that shows the two percentages of Anidulafungin employed (25%-40%), MIC and FICI for the considered mixtures antimycotics/Anidulafungin are particularly interesting for C. krusei, C .parapsilosis, C. tropicalis and C. glabrata, a fungal strains whose pharmacological treatment is very difficult at nowadays. It is important to underline the strong synergy between Anidulafungin and TIO against C. parapsilosis ATCC 22019 and C. parapsilosis 1A1. This result is different when these synergistic associations are employed against C. albicans species; in this situation the increasing of Anidulafungin doesn't cause the decrease of FICI moving from a lower to a higher percentage of Anidulafungin. The data illustrate the possibility to obtain a strong reduction for the quantities of the four antimycotics present in the mixtures respect to the value of MIC that can be about 100 times less respect to the value of the MIC for some of the fungal strains. The better values of this reduction were obtained from the mixture with TIO and FLU with Anidulafungin. This synergistic interaction between Anidulafungin and azole is most likely due to the simultaneous inhibition of biosynthesis of (1-3) -D glucan in the fungal cell wall and ergosterol in the cell membrane. This mechanism has been suggested for both the apparently synergistic interactions between echinocandins (cell wall active) and AMB or azole (both cell membrane active) [11] . Moreover our analysis demonstrates that Anidulafungin -azole interactions may be concentration-dependent. In fact the higher percentage of Anidulafungin in combination with FLU resulted in a decrease of synergy observed at lower Anidulafungin dosage. This dose dependent reduction of synergistic interaction may have several mechanism: firstly, it is possible to hypothesize that an increase of Anidulafungin percentage may cause increased wall injury and disruption of the tertiary structure of transmembrane proteins that otherwise would facilitate uptake of azole compounds. Alternatively the higher percentage of Anidulafungin may also result in secondary injury to the fungal cytoplasmatic structures, including mitochondria, and potentially antagonize the effect of azole on ergosterol biosynthesis. In conclusion in this paper we have shown that in vitro association Anidulafungin/antimycotics is particularly interesting against some fungal species. In detail, these associations were found to produce a substantial Anidulafungin and antimycotics reduction against some nonCandida spp. as C. parapsilosis, C. krusei, C. glabrata. Moreover a good synergistic action was observed on all used fungal clinical strains. Taken together, the results of this study represents a good data to support future investigations in this area and should improve outcomes among patients with these serious fungal infections. If anything, the range of in vitro results shows that almost any results can be achieved for any combination; there are general trends, but is appears that the differences among strains so as in relative drug dosage, make data aggregation difficult. Moreover these in vitro results expand upon what has been reported elsewhere concerning the activity of Anidulafungin and other antimycotics drugs in combination versus Candida spp. as resistances emerge among these fungal pathogens combination treatments could assume a valuable therapeutic role [34] .
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